Fennec price target lowered to $13 from $15 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Fennec Pharmaceuticals to $13 from $15 and keeps a Buy rating on the shares post the Q2 report. The analyst says slow Pedmark uptake necessitates reduced forecasts.